A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study

Part of paid clinical trials in San Diego, California.

Sponsor
Invenio Imaging Inc.
Study ID
NCT07045103
Status
Recruiting

Conditions

  • Lung Biopsy

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The ON-SITE study represents a prospective, observational study focused on the training/tuning and pivotal validation of deep learning algorithms that detect cell/tissue morphology suspicious for cancer in biopsies of peripheral lung nodules/masses and mediastinal/hilar lymph nodes imaged with the NIO Laser Imaging System in the procedure room without requiring traditional sample processing. The study includes four arms based on biopsy location and biopsy modality/tool: 1. Transbronchial forceps biopsy of peripheral lung nodules/masses (peripheral-TBBx) 2. Transbronchial needle aspiration biopsy of peripheral lung nodules/masses (peripheral TBNA) 3. Transbronchial needle aspiration biopsy of mediastinal/hilar lymph nodes (EBUS-TBNA) 4. Transbronchial cryo biopsy of peripheral lung nodules/masses (peripheral-CBx)

Key Dates

Start date
Dec 21, 2023
Status verified
Jun 2025
Primary completion
Apr 30, 2026
Completion
May 31, 2026

Study Design

Enrollment
900 participants (estimated)

Arms

  • Arm: ON-SITE Patients
    Participants must fulfill all of the following criteria in order to be eligible for the study: 1. The patient or legal guardian is willing and able to understand, sign and date the Ethics committee-approved study specific Informed Consent Form. 2. The patient is 22 years of age or older. 3. The patient is scheduled for routinely indicated staging of the mediastinum (EBUS-TBNA) and planned peripheral lung biopsy procedure (peripheral-TBBx/TBNA) with an intermediate to high pretest probability of lung cancer based on clinician suspicion. 4. The patient can tolerate the clinical procedure as indicated.

Primary Outcome Measure

Peripheral TBBx and CBx Co-primary Endpoints [ Time Frame: From enrollment to the End of the Procedure. ]

Locations (7)

FacilityCityStateZIPSite coordinators
UC San DiegoSan DiegoCalifornia92037
George Z Cheng, MD
619-543-5840
George Z Cheng, MD (PRINCIPAL_INVESTIGATOR)
Mayo Clinic JacksonvilleJacksonvilleFlorida32224
Bryan Husta, MD
(904) 953-2861
Bryan Husta, MD (PRINCIPAL_INVESTIGATOR)
Corewell HealthGrand RapidsMichigan49503
Gustavo Cumbo-Nachelli, MD
616-821-8890
Gustavo Cumbo-Nachelli, MD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
Montefiore Medical CenterThe BronxNew York10467
Daniel Da Costa, MD
718-920-6441
Daniel Da Costa, MD (PRINCIPAL_INVESTIGATOR)
UNC Medical CenterChapel HillNorth Carolina27514
Jason Akulian, MD
860-770-4835
Jason Akulian, MD (PRINCIPAL_INVESTIGATOR)
MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in San Diego, CA